• Barry M Steiglitz, Robert J Maher, Kenneth R Gratz, Sandra Schlosser, Jenna Foster, Swati Pradhan-Bhatt, Allen R Comer, and Allen-HoffmannB LynnBLDepartment of Pathology, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA..
• Stratatech, a Mallinckrodt Company, Madison, WI, USA. Electronic address: barry.steiglitz@gmail.com.
• Burns. 2024 Mar 1; 50 (2): 424432424-432.

BackgroundStrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat) is an FDA-approved viable bioengineered allogeneic cellularized construct for adult patients with deep partial-thickness burns requiring surgery. We characterized the structural and functional properties of StrataGraft to improve product understanding by evaluating extracellular matrix (ECM) molecule distribution and secreted protein factor expression in vitro.MethodsECM protein expression was determined using indirect immunofluorescence on construct cross sections using commercial antibodies against collagen III, IV, VI, laminin-332, and decorin. Human collagen I expression was verified by enzyme-linked immunosorbent assay (ELISA) for collagen I C-terminal propeptide. Soluble protein factor secretion was quantified by multiplex biomarker assays and singleplex ELISA in conditioned media from meshed constructs.ResultsStrataGraft cellular components produced collagen I, collagen III, collagen VI, and decorin in patterns indicating an organized ECM. Distributions of collagen IV and laminin-332 indicated formation of basement membranes and dermal-epidermal junctions. Soluble protein factors were observed in the pg/cm2/h range from 1 h to the experiment end at 168 h.ConclusionsThe organization of the ECM proteins was like human skin and the viable cellular components provided sustained secretion of soluble wound healing factors, making StrataGraft an attractive option for treating severe burns.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

19 keywords...

hide…